APA (7th ed.) Citation

B, W., SL, G., G, G., E, H., M, H., L, K., . . . C, H. (2012). Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MS. Journal of neurology, 259(5), 898. https://doi.org/10.1007/s00415-011-6275-7

Chicago Style (17th ed.) Citation

B, Weinstock-Guttman, et al. "Additional Efficacy Endpoints from Pivotal Natalizumab Trials in Relapsing-remitting MS." Journal of Neurology 259, no. 5 (2012): 898. https://doi.org/10.1007/s00415-011-6275-7.

MLA (9th ed.) Citation

B, Weinstock-Guttman, et al. "Additional Efficacy Endpoints from Pivotal Natalizumab Trials in Relapsing-remitting MS." Journal of Neurology, vol. 259, no. 5, 2012, p. 898, https://doi.org/10.1007/s00415-011-6275-7.